Biocardia Stock Math Transform Inverse Tangent Over Price Movement
| BCDA Stock | USD 1.26 -0.01 -0.79% |
| Symbol |
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Biocardia Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Biocardia price patterns.
Biocardia Technical Analysis Modules
Most technical analysis of Biocardia help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Biocardia from various momentum indicators to cycle indicators. When you analyze Biocardia charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. Biocardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. A high-level view of Biocardia emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 5.21. Biocardia has a market cap of 13.48 M, ROE of -3.17%.
Methodology
Unless otherwise specified, financial data for Biocardia is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Biocardia (USA Stocks:BCDA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Biocardia may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardLearn to be your own money manager
Tracking Biocardia inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
| All Next | Launch Module |
Biocardia pair trading
Pair trading with Biocardia can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Biocardia Pair Trading
Biocardia Pair Trading Analysis
Correlation analysis helps investors find suitable substitutes for Biocardia during tax-loss harvesting periods. Selling Biocardia at a loss and immediately repurchasing it would violate IRS wash-sale rules, so a correlated replacement asset is required to maintain portfolio.
Measuring the statistical correlation of Biocardia against other instruments helps investors understand portfolio diversification. A correlation near zero implies that Biocardia provides genuine diversification benefits, while high positive correlations suggest redundant exposures.
Correlation analysis and pair trading evaluation for Biocardia can be used to frame hedging context. The context can be applied within sectors, industries, or broader universes.More Resources for Biocardia Stock Analysis
A structured review of Biocardia often starts with core financial statements and trend context. Financial ratios provide context for profitability, efficiency, and growth trends. Below are reports that help frame Biocardia Stock in context:Biocardia has a market cap of 13.48 M, ROE of -3.17%. Use Trending Equities to explore allocation context. This includes a position in Biocardia across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. For more information on how to buy Biocardia Stock please use our How to Buy Biocardia Stock guide.Analysis related to Biocardia should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Stocks Directory module to find actively traded stocks across global markets.
The market value of Biocardia is measured differently than book value, which reflects Biocardia accounting equity. Biocardia's market capitalization is 13.48 M. With a P/B ratio of 5.21, the market values Biocardia well above its book equity. Enterprise value stands at 9.04 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that Biocardia's intrinsic value and market price are different measures derived from different inputs. For Biocardia, key inputs include a P/B ratio of 5.21, ROE of -3.17%, and revenue of 58 K. Trading price represents the transaction level agreed by market participants.